Ritonavir Completed Phase 4 Trials for High Cholesterol / Human Immunodeficiency Virus (HIV) Infections Treatment

IndicationsStatusPurposePhase
CompletedTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT01102972A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
NCT02159599Study to Evaluate Darunavir/Ritonavir + Lamivudine Versus Continuing With Darunavir/Ritonavir + Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV Infected Subject
NCT01351740Switch to Unboosted Atazanavir With Tenofovir Study
NCT01307488Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
NCT01166477Clinical Trial, Open-label, Randomised, in Order to Compare the Quality of Life for Those VIH+ Patients That Start With Monotherapy on LPV/r Tablets Vs. Triple Therapy With a Boosted Protease Inhibitor
NCT00281606A Multicenter Study to Assess the Tolerability of Once Daily Lopinavir/Ritonavir (LPV/r) Liquid Versus Capsules
NCT00234975Safety of Lopinavir/Ritonavir (Kaletra) in HIV/HCV Co-infected Subjects vs Baseline Liver Biopsy Metavir Score
NCT00114933OK 2004 Study (Only Kaletra 2004 Study): Study to Evaluate Suspending Nucleosides From Triple-Drug Therapy in HIV Subjects
NCT01869634Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART
NCT00717067Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function
NCT00607958Clinical Trial to Assess the Security of the Dose Reduction of Ritonavir in HIV-Infected Patients in Treatment With Tipranavir/Ritonavir 500/200 mg Every 12 Hours
NCT00611039Evaluate the Efficacy and Security of Darunavir/Ritonavir 900/100 mg Once a Day as an Antiretroviral Treatment Simplification Strategy
NCT00379405Saquinavir/Ritonavir in Single Therapy as Maintenance Treatment
NCT00355719Study to Evaluate the Influence of Nevirapine to Atazanavir in Steady State Equilibrium in HIV Patients
NCT00931463A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen
NCT00752037Safety Study of Lopinavir/Ritonavir With Raltegravir in HIV-infected Patients
NCT00677300Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients
NCT00148759Kaletra Sex/Gender Pharmacokinetics (PK) Study
NCT00148785A Pharmacokinetic (PK) Study of a Combination of Indinavir, Ritonavir, and Amprenavir
NCT00145795A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment
NCT00532168Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl
NCT00552240Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT)
NCT00700115Kaletra-isentress Treatment Evaluation
NCT00159224Induction-maintenance of Lopinavir/r in HIV-infected Subjects
NCT00242216The Once A Day Protease Inhibitor Regimens
NCT00885482Atazanavir and Lamivudine for Treatment Simplification
NCT00335686Study on the Effect of Kaletra + Nevirapine as Maintenance Bitherapy Compared to a Triple Therapy Including Kaletra + Analogues in HIV Patients
NCT00207142Induction-Maintenance With Atazanavir in HIV Naïve Patients (The INDUMA Study)
NCT00438152Lopinavir Capsules to Kaletra or Invirase Tablets
NCT00224445Boosted Atazanavir and Truvada Given Once-Daily - BATON Study
NCT00762892Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients
NCT00544128Comparison of Epzicom and Truvada for the Initial Once Daily HIV Treatment
NCT00540137The CogNaive Study: Assessing Changes in Neurocognitive Function in Treatment Naïve HIV-1 Positive Subjects
NCT00994344Clinical Study to Evaluate the Efficacy and Safety of Lopinavir/Ritonavir Monotherapy Versus Darunavir/Ritonavir Monotherapies as Simplification Switching Strategies of PI/NNRTI-Triple Therapy Based-Regimens
NCT00084253Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients
NCT01599364Atazanavir/r + Lamivudine Dual Therapy
NCT00648999Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients
NCT01234116Post-Exposure Prophylaxis in Health Care Workers
NCT00335322ALTAIR - Alternative Antiretroviral Strategies : a Comparison of Three Initial Regimens
NCT01116817Study to Compare the Virologic Efficacy in Cerebrospinal Fluid (CSF) and Neurocognitive State in Patients Infected by HIV-1 Long-term Treatment (> 3 Years) With Lopinavir / Ritonavir Monotherapy
NCT01513122Bone and Body Comp: A Sub Study of the SECOND-LINE Study
NCT01423812DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects
NCT00342355Antiretroviral Therapy for Advanced HIV Disease in South Africa
NCT00335192To Determine if There Are Pharmacokinetic Interactions at Plasma or Intracellular Level Between Nucleosides and Tenofovir
NCT01445223A Study on Antiretroviral Therapy (ART) Naïve Patients On Different Regimens to Treat Hiv (NORTHIV)
NCT01935674Treatment With Rosuvastatin Versus Switching PI (Protease Inhibitor) in Patients HIV With High Cholesterol Levels
NCT01680536A Study to Assess Cerebrospinal Fluid INflammatory Markers After Addition of Maraviroc to MONotherapy Darunavir/Ritonavir - The CINAMMON Study
NCT01581853Pilot Simplification Study to Lopinavir/Ritonavir 800/200 mg Monotherapy Regimen Once Daily
NCT01736761A Phase IV, Open-label Single-arm Study Investigating the Pharmacokinetics and Pharmacodynamics of the Antiretroviral Combination of Rilpivirine and Ritonavirboosted Darunavir in Therapy-naive HIV-1 Infected Patients.
NCT00335270A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908Ritonavir Given With Abacavir/Lamivudine Fixed Dose Combination
NCT00979706Immune-based Therapy Pilot Study for the Treatment of Primary HIV Infection (PHI-IMD).
NCT00757783Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment